Drugs / GS-CDA1
last change Jan 2010 re-read 2 minutes ago

GS-CDA1

Monoclonal antibody

Developed for
Clostridium difficile colitis
Investigated by
MassBiologics · Medarex

Trials 1 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00350298 Jul 2006 → Jun 2008 Clostridium difficile colitis MassBiologics Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as GS-CDA1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00350298
Action Inhibit “two neutralizing, fully human monoclonal antibodies against C. difficile toxins A (CDA1) and B (CDB1).” PMID 20089970 Jan 2010
Modality Monoclonal antibody “a human monoclonal antibody to C. difficile toxin A (GS-CDA1)” NCT00350298